This trial includes patients with AML, MDS, CML or ALL who are at high risk of relapse after alloSCT and utilizes infusions of WT-1-specific donor T-cells that are expanded in vitro, cryopreserved, and then infused at the time of recurrence or appearance of MRD. Here, WT1 is linked to acute lymphoblastic leukemia.